

Supplementary Table S1: Line listing of adverse events of special interest

MedDRA preferred term	Severity grade	Outcome of event	Relationship to investigational product	post-first vaccination ¹	post-second vaccination ²	Post booster vaccination	Age	Gender	Ethnicity	HIV status	Prior COVID infection	Co-morbidities
Hyperglycaemia	Severe	Recovered/Resolved	No	Yes			55	F	Black African	Positive	No	Diabetes
Joint Swelling	Moderate	Not recovered/Not resolved	Yes	Yes*			32	M	Black African	Negative	No	None
Joint Swelling	Moderate	Not recovered/Not resolved	Yes	Yes*			32	M	Black African	Negative	No	None
Arthralgia	Moderate	Recovered/Resolved	Yes	Yes			34	F	Black African	Positive	Yes	None
Dizziness	Mild	Recovered/Resolved	Yes	Yes	Yes*		31	M	Black African	Negative	No	None
Pemphigoid	Moderate	Recovered/Resolved	Yes	Yes	Yes*		40	F	Black African	Negative	No	Hypertension, Obesity
Hyperviscosity Syndrome	Moderate	Recovering/Resolving	No	Yes			57	F	Black African	Negative	No	Hypertension, Obesity
Hyperviscosity Syndrome	Moderate	Not recovered/Not resolved	No	Yes			57	F	Black African	Negative	No	Hypertension, Obesity

¹ Includes SAEs occurring 28 days post-first vaccination

² Includes SAEs occurring 28 days post-first vaccination

*within 21 days of vaccination